Created at Source Raw Value Validated value
May 14, 2021, 12:45 a.m. oms

[{"arm_notes": "", "treatment_id": null, "treatment_name": "The study consists of 5 single dose cohorts and 1 multiple dose cohort which will be studied sequentially. Participants in each single dose cohort will receive a single dose of either placebo or 5 mcg; 15 mcg; 30 mcg; 50 mcg or 100 mcg of REVTx-99 intranasally. Participants in the multiple dose cohort will receive 100 mcg of REVTx-99 intranasally every day for 5 days. Study drug will be administered by a registered nurse.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "5 mcg; IN", "treatment_id": 1118, "treatment_name": "Revtx-99", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "15 mcg; IN", "treatment_id": 1118, "treatment_name": "Revtx-99", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "30 mcg; IN", "treatment_id": 1118, "treatment_name": "Revtx-99", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "50 mcg ; IN", "treatment_id": 1118, "treatment_name": "Revtx-99", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "100 mcg ; IN", "treatment_id": 1118, "treatment_name": "Revtx-99", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "100 mcg ; 5 days ; IN", "treatment_id": 1118, "treatment_name": "Revtx-99", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

Oct. 29, 2020, 11:45 p.m. oms

[{"arm_notes": "", "treatment_id": null, "treatment_name": "The study consists of 4 cohorts which will be studied sequentially. Participants in each cohort will receive a single dose of either placebo or 5 mcg; 15 mcg; 30 mcg or 50 mcg of REVTx-99 intranasally. Study drug will be administered by a registered nurse.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]